Lyndavel Mechanism of Action

Pharmacotherapeutic group: Progestogens. ATC code: G03AC06.
Pharmacology: Pharmacodynamics: Medroxyprogesterone Acetate exerts anti-estrogenic, anti-androgenic and anti-gonadotrophic effects.
Mechanism of Action: Medroxyprogesterone Acetate (LYNDAVEL) works primarily by preventing the release of eggs from the ovaries (ovulation). Also, it prevents pregnancy by thickening and decreasing the quality of cervical mucus, an anti-estrogen effect that prevents sperm penetration.
Pharmacokinetics: Parenteral Medroxyprogesterone Acetate (MPA) is a long acting progestational steroid. The long duration of action results from its slow absorption from the injection site. Immediately after injection of 150 mg MPA, plasma levels were 1.7 ± 0.3 nmol/l. Two weeks later, levels were 6.8 ± 0.8 nmol/l. Concentrations fell to the initial levels by the end of 12 weeks. At lower doses, plasma levels of MPA appear directly related to the dose administered. Serum accumulation over time was not demonstrated. MPA is eliminated via fecal and urinary excretion. Plasma half-life is about six weeks after a single intramuscular injection. At least 11 metabolites have been reported. And almost all are excreted in the urine.